170 related articles for article (PubMed ID: 15766724)
1. Semiautomated cell-free conversion of prion protein: applications for high-throughput screening of potential antiprion drugs.
Breydo L; Bocharova OV; Baskakov IV
Anal Biochem; 2005 Apr; 339(1):165-73. PubMed ID: 15766724
[TBL] [Abstract][Full Text] [Related]
2. In vitro conversion of full-length mammalian prion protein produces amyloid form with physical properties of PrP(Sc).
Bocharova OV; Breydo L; Parfenov AS; Salnikov VV; Baskakov IV
J Mol Biol; 2005 Feb; 346(2):645-59. PubMed ID: 15670611
[TBL] [Abstract][Full Text] [Related]
3. Spontaneous and BSE-prion-seeded amyloid formation of full length recombinant bovine prion protein.
Panza G; Stöhr J; Dumpitak C; Papathanassiou D; Weiss J; Riesner D; Willbold D; Birkmann E
Biochem Biophys Res Commun; 2008 Sep; 373(4):493-7. PubMed ID: 18585368
[TBL] [Abstract][Full Text] [Related]
4. Sulfated glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free formation of protease-resistant prion protein.
Wong C; Xiong LW; Horiuchi M; Raymond L; Wehrly K; Chesebro B; Caughey B
EMBO J; 2001 Feb; 20(3):377-86. PubMed ID: 11157745
[TBL] [Abstract][Full Text] [Related]
5. Assembly of natural and recombinant prion protein into fibrils.
Leffers KW; Wille H; Stöhr J; Junger E; Prusiner SB; Riesner D
Biol Chem; 2005 Jun; 386(6):569-80. PubMed ID: 16006244
[TBL] [Abstract][Full Text] [Related]
6. Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils.
Bocharova OV; Breydo L; Salnikov VV; Baskakov IV
Biochemistry; 2005 May; 44(18):6776-87. PubMed ID: 15865423
[TBL] [Abstract][Full Text] [Related]
7. Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets.
Bertsch U; Winklhofer KF; Hirschberger T; Bieschke J; Weber P; Hartl FU; Tavan P; Tatzelt J; Kretzschmar HA; Giese A
J Virol; 2005 Jun; 79(12):7785-91. PubMed ID: 15919931
[TBL] [Abstract][Full Text] [Related]
8. Screening a library of potential prion therapeutics against cellular prion proteins and insights into their mode of biological activities by surface plasmon resonance.
Touil F; Pratt S; Mutter R; Chen B
J Pharm Biomed Anal; 2006 Mar; 40(4):822-32. PubMed ID: 16242887
[TBL] [Abstract][Full Text] [Related]
9. The emerging principles of mammalian prion propagation and transmissibility barriers: Insight from studies in vitro.
Surewicz WK; Jones EM; Apetri AC
Acc Chem Res; 2006 Sep; 39(9):654-62. PubMed ID: 16981682
[TBL] [Abstract][Full Text] [Related]
10. Photo-induced crosslinking of prion protein oligomers and prions.
Piening N; Weber P; Högen T; Beekes M; Kretzschmar H; Giese A
Amyloid; 2006 Jun; 13(2):67-77. PubMed ID: 16911960
[TBL] [Abstract][Full Text] [Related]
11. In vitro self-propagation of recombinant PrPSc-like conformation generated in the yeast cytoplasm.
Yang W; Yang H; Tien P
FEBS Lett; 2006 Jul; 580(17):4231-5. PubMed ID: 16831424
[TBL] [Abstract][Full Text] [Related]
12. Structural insights into the interaction between prion protein and nucleic acid.
Lima LM; Cordeiro Y; Tinoco LW; Marques AF; Oliveira CL; Sampath S; Kodali R; Choi G; Foguel D; Torriani I; Caughey B; Silva JL
Biochemistry; 2006 Aug; 45(30):9180-7. PubMed ID: 16866364
[TBL] [Abstract][Full Text] [Related]
13. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
[TBL] [Abstract][Full Text] [Related]
14. The role of rafts in the fibrillization and aggregation of prions.
Pinheiro TJ
Chem Phys Lipids; 2006 Jun; 141(1-2):66-71. PubMed ID: 16647049
[TBL] [Abstract][Full Text] [Related]
15. Lactoferrin induces cell surface retention of prion protein and inhibits prion accumulation.
Iwamaru Y; Shimizu Y; Imamura M; Murayama Y; Endo R; Tagawa Y; Ushiki-Kaku Y; Takenouchi T; Kitani H; Mohri S; Yokoyama T; Okada H
J Neurochem; 2008 Nov; 107(3):636-46. PubMed ID: 18717818
[TBL] [Abstract][Full Text] [Related]
16. Monitoring prion protein stability by NMR.
Julien O; Graether SP; Sykes BD
J Toxicol Environ Health A; 2009; 72(17-18):1069-74. PubMed ID: 19697241
[TBL] [Abstract][Full Text] [Related]
17. In vitro conversion of mammalian prion protein into amyloid fibrils displays unusual features.
Baskakov IV; Bocharova OV
Biochemistry; 2005 Feb; 44(7):2339-48. PubMed ID: 15709746
[TBL] [Abstract][Full Text] [Related]
18. Detection, quantification, and glycotyping of prion protein in specifically activated enzyme-linked immunosorbent assay plates.
Triantaphyllidou IE; Sklaviadis T; Vynios DH
Anal Biochem; 2006 Dec; 359(2):176-82. PubMed ID: 17092479
[TBL] [Abstract][Full Text] [Related]
19. Mapping of possible prion protein self-interaction domains using peptide arrays.
Rigter A; Langeveld JP; Timmers-Parohi D; Jacobs JG; Moonen PL; Bossers A
BMC Biochem; 2007 Apr; 8():6. PubMed ID: 17430579
[TBL] [Abstract][Full Text] [Related]
20. Hot spots in prion protein for pathogenic conversion.
Kuwata K; Nishida N; Matsumoto T; Kamatari YO; Hosokawa-Muto J; Kodama K; Nakamura HK; Kimura K; Kawasaki M; Takakura Y; Shirabe S; Takata J; Kataoka Y; Katamine S
Proc Natl Acad Sci U S A; 2007 Jul; 104(29):11921-6. PubMed ID: 17616582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
